Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Oxford COVID-19 vaccine trials produce robust immune response in elderly - FT

Mon, 26th Oct 2020 06:14

Oct 26 (Reuters) - Early results from tests for a
coronavirus vaccine being developed by the University of Oxford,
in collaboration with AstraZeneca Plc, show it produces
a robust immune response in elderly people, the group at highest
risk, the Financial Times reported on Monday.

It has been discovered that the vaccine triggers protective
antibodies and T-cells in older age groups, the newspaper said https://on.ft.com/3kxKyJI,
citing two people familiar with the finding, encouraging
researchers as they seek evidence that it will spare those in
later life from serious illness or death from the virus.

The findings echo data released in July which showed the
vaccine generated "robust immune responses" in a group of
healthy adults aged between 18 and 55, the newspaper reported,
citing people aware of the results from so-called immunogenicity
blood tests.

But the FT cautioned that positive immunogenicity tests do
not guarantee that the vaccine will ultimately prove safe and
effective in older people.

AstraZeneca, which is developing the vaccine with Oxford
University researchers, is seen as a frontrunner in the race to
produce a vaccine to protect against COVID-19.

Details of the finding are expected to be published shortly
in a clinical journal, the FT said, without naming a journal.

Oxford and AstraZeneca did not immediately respond to
Reuters' request for comments.
(Reporting by Bhargav Acharya in Bengaluru; Editing by Simon

Related Shares

More News

Monday broker round-up

(Sharecast News) - Diploma: Numis upgrades to add with a target price of 3,250p.

Today 14:38

UK eases lockdown restrictions despite Indian variant threat

(Sharecast News) - The UK relaxed social and economic restrictions on Monday despite the looming threat of the Indian Covid-19 variant.

Today 10:16

Friday broker round-up

(Sharecast News) - NCC Group: Canaccord upgrades to buy with a target price of 318p.

14 May 21 12:57

UK prepares to 'flex' vaccination program to tackle Indian Covid-19 variant

(Sharecast News) - UK vaccines minister Nadhim Zahawi said on Friday that the government was gearing up to "flex" its inoculation program in order to tackle the new coronavirus variant first detected in India.

14 May 21 11:16

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.